PT2041308E - Método para a detecção e diagnóstico do cancro envolvendo iniciadores e sondas para a detecção específica do marcador mage�a3 - Google Patents

Método para a detecção e diagnóstico do cancro envolvendo iniciadores e sondas para a detecção específica do marcador mage�a3 Download PDF

Info

Publication number
PT2041308E
PT2041308E PT07786793T PT07786793T PT2041308E PT 2041308 E PT2041308 E PT 2041308E PT 07786793 T PT07786793 T PT 07786793T PT 07786793 T PT07786793 T PT 07786793T PT 2041308 E PT2041308 E PT 2041308E
Authority
PT
Portugal
Prior art keywords
mage
seq
probe
primer
pcr
Prior art date
Application number
PT07786793T
Other languages
English (en)
Portuguese (pt)
Inventor
Thierry Coche
Olivier Gruselle
Gabriele Anne-Marie Beer
Dennis Salonga
Craig Lawrence Stephens
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PT2041308E publication Critical patent/PT2041308E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT07786793T 2006-06-21 2007-06-21 Método para a detecção e diagnóstico do cancro envolvendo iniciadores e sondas para a detecção específica do marcador mage�a3 PT2041308E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612342.6A GB0612342D0 (en) 2006-06-21 2006-06-21 Method

Publications (1)

Publication Number Publication Date
PT2041308E true PT2041308E (pt) 2012-10-09

Family

ID=36803668

Family Applications (1)

Application Number Title Priority Date Filing Date
PT07786793T PT2041308E (pt) 2006-06-21 2007-06-21 Método para a detecção e diagnóstico do cancro envolvendo iniciadores e sondas para a detecção específica do marcador mage�a3

Country Status (27)

Country Link
US (1) US8936919B2 (cg-RX-API-DMAC7.html)
EP (1) EP2041308B1 (cg-RX-API-DMAC7.html)
JP (2) JP2009540812A (cg-RX-API-DMAC7.html)
KR (1) KR101455589B1 (cg-RX-API-DMAC7.html)
CN (1) CN101506383B (cg-RX-API-DMAC7.html)
AU (1) AU2007263019B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0713599A2 (cg-RX-API-DMAC7.html)
CA (1) CA2656909A1 (cg-RX-API-DMAC7.html)
CO (1) CO6140072A2 (cg-RX-API-DMAC7.html)
CY (1) CY1113290T1 (cg-RX-API-DMAC7.html)
DK (1) DK2041308T3 (cg-RX-API-DMAC7.html)
EA (1) EA016347B1 (cg-RX-API-DMAC7.html)
ES (1) ES2389513T3 (cg-RX-API-DMAC7.html)
GB (1) GB0612342D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20120761T1 (cg-RX-API-DMAC7.html)
IL (1) IL195975A (cg-RX-API-DMAC7.html)
MA (1) MA30565B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008016493A (cg-RX-API-DMAC7.html)
MY (1) MY147511A (cg-RX-API-DMAC7.html)
NO (1) NO20085290L (cg-RX-API-DMAC7.html)
NZ (1) NZ573809A (cg-RX-API-DMAC7.html)
PL (1) PL2041308T3 (cg-RX-API-DMAC7.html)
PT (1) PT2041308E (cg-RX-API-DMAC7.html)
SI (1) SI2041308T1 (cg-RX-API-DMAC7.html)
UA (1) UA95956C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007147876A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200810695B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596545A (en) 2007-09-17 2013-05-31 Glaxosmithkline Biolog Sa Improved detection of mage-a expression
US8987423B2 (en) * 2010-07-22 2015-03-24 Glaxosmithkline Biologicals, S.A. MAGE antigen binding proteins
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
IL106610A0 (en) * 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
ATE209690T1 (de) * 1994-03-01 2001-12-15 Ludwig Inst Cancer Res Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
US5985571A (en) * 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
AU5992999A (en) 1998-10-02 2000-04-26 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
US6358679B1 (en) * 2000-08-24 2002-03-19 Pe Corporation (Ny) Methods for external controls for nucleic acid amplification
US6635425B2 (en) * 2001-01-05 2003-10-21 Molecular Staging, Inc. 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms
DE60234115D1 (de) * 2001-11-29 2009-12-03 Dandrit Biotech As Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
ATE522620T1 (de) * 2002-11-14 2011-09-15 Wayne John Cancer Inst Nachweis von micrometastasierung von melanomen und brustkrebs an in paraffin eingegbetteten, von tumoren abführenden lymphknoten mittels quantitativer multimaker rt-pcr
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Also Published As

Publication number Publication date
IL195975A (en) 2012-08-30
PL2041308T3 (pl) 2012-11-30
US8936919B2 (en) 2015-01-20
GB0612342D0 (en) 2006-08-02
ES2389513T3 (es) 2012-10-26
HRP20120761T1 (hr) 2012-10-31
CA2656909A1 (en) 2007-12-27
CY1113290T1 (el) 2016-04-13
HK1127627A1 (en) 2009-10-02
WO2007147876A2 (en) 2007-12-27
JP2009540812A (ja) 2009-11-26
MX2008016493A (es) 2009-05-21
EA200802356A1 (ru) 2009-06-30
JP2013046630A (ja) 2013-03-07
SI2041308T1 (sl) 2012-10-30
EP2041308B1 (en) 2012-07-11
DK2041308T3 (da) 2012-10-08
MA30565B1 (fr) 2009-07-01
ZA200810695B (en) 2014-03-26
US20120040341A1 (en) 2012-02-16
NZ573809A (en) 2011-12-22
JP5705191B2 (ja) 2015-04-22
BRPI0713599A2 (pt) 2012-11-06
AU2007263019B2 (en) 2012-11-08
UA95956C2 (uk) 2011-09-26
WO2007147876A3 (en) 2008-05-15
CO6140072A2 (es) 2010-03-19
CN101506383A (zh) 2009-08-12
CN101506383B (zh) 2013-08-28
KR101455589B1 (ko) 2014-10-28
AU2007263019A1 (en) 2007-12-27
KR20090034900A (ko) 2009-04-08
IL195975A0 (en) 2009-09-01
NO20085290L (no) 2009-01-19
EA016347B1 (ru) 2012-04-30
MY147511A (en) 2012-12-31
EP2041308A2 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
KR101437718B1 (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
JP6032616B2 (ja) Ｋｉｆ５ｂ遺伝子とｒｅｔ遺伝子との融合遺伝子、並びに該融合遺伝子を標的としたがん治療の有効性を判定する方法
JP5009787B2 (ja) Ｅｒｇ遺伝子を単独でまたは前立腺癌中で過剰発現もしくは過少発現される他の遺伝子と組み合わせて用いる、前立腺癌を診断または治療する方法
RU2491289C2 (ru) Полинуклеотидные праймеры
Fischer et al. Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA
CA2877864C (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
Yam et al. EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients
JP5769952B2 (ja) Ｅｍｌ４−ａｌｋ融合遺伝子の高感度検出方法
KR20030081339A (ko) Ｅｒｃｃ１ 및 ｔｓ 발현을 기초로 한 화학요법 섭생을결정하는 방법
CA2752668A1 (en) Method for detecting metastasis of gi cancer
Venesio et al. Oxidative DNA damage drives carcinogenesis in MUTYH-associated-polyposis by specific mutations of mitochondrial and MAPK genes
Yatagai et al. Frequent loss of heterozygosity of SMAD4 locus and prognostic impacts of SMAD4 immunohistochemistry in gastric adenocarcinoma with enteroblastic differentiation
Miyamae et al. Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue
Symvoulakis et al. Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer
EP2041308B1 (en) Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3 marker
JP4272512B2 (ja) 癌
KR102600344B1 (ko) Kras 유전자 돌연변이 검출용 조성물 및 이를 포함하는 키트
WO2013177705A1 (en) Genotyping assay for identifying chromosomal rearrangements
Sánchez-Pernaute et al. Overexpression of c-myc and loss of heterozigosity on 2p, 3p, 5q, 17p and 18q in sporadic colorectal carcinoma
WO2016116935A1 (en) Use of rasa2 as a prognostic and therapeutic marker for melanoma
KR102600347B1 (ko) Nras 유전자 돌연변이 검출용 조성물 및 이를 포함하는 키트
US20240415839A1 (en) Identification and Treatment of Cancers Associated with RASGRF1 Gene Fusions
HK1127627B (en) Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3 marker
KR101766005B1 (ko) 폐암 환자의 생존기간 예측용 키트와 생존기간 예측을 위한 정보 제공 방법
KR101805977B1 (ko) 폐암 환자의 생존기간 예측용 키트와 생존기간 예측을 위한 정보 제공 방법